Hikma Pharmaceuticals PLC (LSE: HIK)
Health Care · Pharmaceuticals · GB
£16.12
+0.31% today · -12.9% 1Y
Hikma Pharmaceuticals PLC (LSE: HIK) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $4.46B and employs 9,500 people.
Over the last twelve months the share price has lost 12.9%, trading between 11.87 and 18.65.
Tweenvest scores Hikma Pharmaceuticals PLC across four factors: quality 82/100, value 66/100, growth 39/100, dividend 100/100. Its strongest factor is dividend.
HIK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.46B
- Revenue (TTM)
- $3.42B
- P/E
- 12.17
- EPS
- 1.76
- Dividend yield
- 3.96%
- Beta (5Y)
- 0.65
- 52-week high
- £18.65
- 52-week low
- £11.87
- Avg volume (3M)
- —
- Shares outstanding
- 208.95M
- Employees
- 9,500
- Next earnings
- —
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.
- ISIN
- GB00B0LCW083
- Founded
- 1978
- Listed since
- Nov 1, 2005
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Definium Therapeutics, Inc.NasdaqGS: DFTX | $4.96B | $36.90 | +7.96% |
| Humanwell Healthcare (Group) Co.,Ltd.SHSE: 600079 | $4.69B | CN¥19.23 | +0.31% |
| Hanmi Pharm. Co., Ltd.KOSE: A128940 | $4.54B | ₩480,500.00 | -5.04% |
| Sumitomo Pharma Co., Ltd.TSE: 4506 | $4.51B | ¥1,591.50 | -1.36% |
| Dong-E-E-Jiao Co., Ltd.SZSE: 000423 | $4.45B | CN¥46.68 | +0.56% |
| GlaxoSmithKline Pharmaceuticals LimitedBSE: 500660 | $4.45B | Rs2,539.80 | -8.46% |
| Ajanta Pharma LimitedNSEI: AJANTPHARM | $4.40B | Rs3,410.10 | -4.77% |
| Dottikon ES Holding AGSWX: DESN | $4.32B | CHF260.00 | +1.36% |
Figures last refreshed Oct 11, 2026.